RNA
Atrium Therapeutics, Inc. NASDAQ Listed Feb 27, 2026$12.94
+2.21%
vs $12.66
Mkt Cap $221.5M
52w Low $11.55
27.9% of range
52w High $16.54
50d MA $12.98
200d MA $13.35
P/E (TTM)
-2.9x
EV/EBITDA
—
P/B
1.1x
Debt/Equity
0.0x
ROE
-40.5%
P/FCF
-5.2x
RSI (14)
53.60
ATR (14)
$0.49
Beta
0.00
50d MA
$12.98
200d MA
$13.35
Avg Volume
197.8K
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
10578 Science Center Drive · San Diego, CA 92121 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | AMC | -1.24 | -0.61 | +50.8% | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 18 | Cantor Fitzgerald | Initiates | Overweight | $25 | $12.48 | $12.83 | +2.8% | +1.4% | — | — | — | — |
| May 15 | Leerink Partners | Initiates | Outperform | $25 | $13.27 | $13.48 | +1.6% | -0.3% | -2.1% | +0.0% | -1.8% | +2.5% |
| Nov 11 | Chardan Capital | Maintains | Neutral → Neutral | — | — | — | — | — | — | — | — | — |
| Oct 29 | TD Cowen | Downgrade | Buy → Hold | — | — | — | — | — | — | — | — | — |
| Oct 28 | RBC Capital | Downgrade | Outperform → Sector Perform | — | — | — | — | — | — | — | — | — |
| Oct 28 | Chardan Capital | Downgrade | Buy → Neutral | — | — | — | — | — | — | — | — | — |
| Oct 27 | Citigroup | Downgrade | Buy → Neutral | — | — | — | — | — | — | — | — | — |
| Oct 27 | Bernstein | Downgrade | Outperform → Market Perform | — | — | — | — | — | — | — | — | — |
| Oct 27 | Raymond James | Downgrade | Strong Buy → Market Perform | — | — | — | — | — | — | — | — | — |
| Oct 27 | Needham | Downgrade | Buy → Hold | — | — | — | — | — | — | — | — | — |
| Oct 27 | Leerink Partners | Downgrade | Outperform → Market Perform | — | — | — | — | — | — | — | — | — |
| Oct 27 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | — | — | — | — | — | — | — | — |
| Sep 22 | Evercore ISI | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| Sep 15 | BofA Securities | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Sep 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Sep 10 | Needham | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Sep 10 | Chardan Capital | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Aug 8 | Wells Fargo | Maintains | Overweight → Overweight | — | — | — | — | — | — | — | — | — |
| Aug 8 | Chardan Capital | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Aug 8 | Barclays | Maintains | Overweight → Overweight | — | — | — | — | — | — | — | — | — |
| Jun 27 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | — | — | — | — | — | — | — | — |
| Jun 10 | Citigroup | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Jun 10 | Barclays | Maintains | Overweight → Overweight | — | — | — | — | — | — | — | — | — |
| Jun 9 | Chardan Capital | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Jun 9 | BofA Securities | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| May 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| May 9 | Chardan Capital | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| May 7 | Chardan Capital | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Apr 9 | Needham | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Mar 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Mar 17 | Chardan Capital | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Mar 17 | Needham | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Mar 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Mar 10 | BofA Securities | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Feb 28 | Barclays | Maintains | Overweight → Overweight | — | — | — | — | — | — | — | — | — |
| Feb 28 | Chardan Capital | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Jan 21 | RBC Capital | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| Jan 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Nov 13 | Chardan Capital | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Nov 13 | Needham | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Oct 31 | Needham | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Oct 30 | Chardan Capital | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Oct 21 | TD Cowen | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Sep 18 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | — | — | — | — | — | — | — | — |
| Sep 16 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | — | — | — | — | — | — | — | — |
| Sep 9 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | — | — | — | — | — | — | — | — |
| Aug 26 | Evercore ISI | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| Aug 13 | Needham | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Aug 12 | Evercore ISI | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| Aug 9 | Chardan Capital | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
No insider trades available.
8-K · 2.02
!! High
Atrium Therapeutics, Inc. -- 8-K 2.02: Earnings Results
May 14
8-K · 5.02
!!! Very High
Atrium Therapeutics, Inc. -- 8-K 5.02: Executive Change
Atrium Therapeutics appointed four new directors following its distribution from Bristol Myers Squibb, signaling completion of the planned spinoff and establishment of independent board governance.
Feb 27
8-K · 5.02
!!! Very High
Atrium Therapeutics, Inc. -- 8-K 5.02: Executive Change
Novartis's acquisition of Atrium Therapeutics closed at $72.00 per share, providing value to optionholders whose stock options exceeded the exercise price.
Feb 27
8-K
Atrium Therapeutics, Inc. -- 8-K Filing
Atrium Therapeutics completed a spin-off from its parent company, creating an independent entity focused on its therapeutic pipeline with separate ownership structure and operational autonomy.
Feb 26
8-K · 7.01
! Medium
Atrium Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Avidity Biosciences plans to distribute all Atrium Therapeutics shares pro rata to its stockholders, creating a spinoff that will give Avidity investors direct ownership in the independent company.
Feb 26
8-K
Atrium Therapeutics, Inc. -- 8-K Filing
Novartis's acquisition of Atrium Therapeutics (RNA) through Avidity Biosciences is progressing toward shareholder vote, with the definitive proxy statement filed January 30, 2026.
Feb 23
8-K
Atrium Therapeutics, Inc. -- 8-K Filing
This filing appears to contain standard forward-looking statement disclaimers rather than material news, providing limited actionable information for investors regarding Atrium Therapeutics' operations or financial condition.
Feb 3
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 626,869 | $8M | New | Mar 2026 |
| 2 | Farallon Capital Management Llc | 349,360 | $5M | New | Mar 2026 |
| 3 | Vanguard Portfolio Management Llc | 344,369 | $5M | New | Mar 2026 |
| 4 | Bellevue Group Ag | 263,096 | $4M | New | Mar 2026 |
| 5 | Arbiter Partners Capital Management Llc | 230,000 | $3M | New | Mar 2026 |
| 6 | Millennium Management | 190,859 | $3M | New | Mar 2026 |
| 7 | Two Sigma Investments, Lp | 178,560 | $2M | New | Mar 2026 |
| 8 | Marble Bar Asset Management Llp | 147,000 | $2M | New | Mar 2026 |
| 9 | Janus Henderson Group Plc | 139,973 | $2M | New | Mar 2026 |
| 10 | Nomura Holdings Inc | 137,380 | $2M | New | Mar 2026 |
| 11 | Bank Of America Corp /de/ | 136,248 | $2M | New | Mar 2026 |
| 12 | Yakira Capital Management, Inc. | 126,645 | $2M | New | Mar 2026 |
| 13 | Citadel Advisors Llc | 109,936 | $1M | New | Mar 2026 |
| 14 | Athos Capital Ltd | 107,965 | $1M | New | Mar 2026 |
| 15 | Northern Trust Corp | 98,585 | $1M | New | Mar 2026 |
| 16 | Exoduspoint Capital Management, Lp | 77,442 | $1M | New | Mar 2026 |
| 17 | Tudor Investment Corp | 71,359 | $954K | New | Mar 2026 |
| 18 | Neuberger Berman Group Llc | 69,294 | $926K | New | Mar 2026 |
| 19 | Adar1 Capital Management, Llc | 57,688 | $771K | New | Mar 2026 |
| 20 | Westchester Capital Management, Llc | 55,236 | $739K | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$221.5M
Enterprise Value
-$48.5M
P/E (TTM)
-2.89x
Forward P/E
—
PEG Ratio
0.00x
P/B
1.07x
P/S
11.89x
P/FCF
-5.20x
EV/EBITDA
—
Shares Out
17.1M
Financials (TTM)
Revenue
$18.6M
Net Income
-$76.7M
EBITDA
-$76.5M
Free Cash Flow
-$42.6M
Op Cash Flow
-$41.1M
EPS Basic
$-4.48
EPS Diluted
$-4.48
EPS Forward
$-5.04
Gross Margin
100.0%
Op Margin
-412.6%
Net Margin
-411.9%
Balance Sheet
Total Assets
$278.4M
Total Liab.
$71.1M
Total Equity
$207.3M
Cash
$270.0M
LT Debt
$0
Book Value/Sh
$12.11
Debt/Equity
0.02x
Current Ratio
6.53
Quick Ratio
6.53
Returns & Growth
ROE
-40.5%
ROA
-35.0%
ROIC
-31.9%
Rev Growth YoY
+0.0%
EPS Growth YoY
—
Price Returns
2W
-2.0%
1M
+1.8%
3M
-11.9%
6M
-11.9%
12M
-11.9%
Technicals
52W High
$16.54
52W Low
$11.55
50d MA
$12.98
200d MA
$13.35
RSI (14)
53.60
ATR (14)
$0.49
Beta
0.00
Avg Volume
198K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 26, 2026 11:11pm
· Source: financialmodelingprep.com